StockData
Metagenomi Therapeutics, Inc. logo

Metagenomi Therapeutics, Inc. (MGX) stock

MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$0.63−0.05 (-7.21%)

Close on Nov 17, 2026Market cap $23.84MP/E –Yield –

Metagenomi Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

No pe ratio figures for Metagenomi Therapeutics

Metagenomi Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Metagenomi Therapeutics figures

See a number that looks wrong?